Background: The objective of the current study was to determine if altered regulation of matrix metalloproteinases (MMPs) may predispose to extracellular matrix degradation, facilitating arterial calcification in chronic kidney disease (CKD) using a progressive model of CKD-MBD, the Cy/+ rat. Methods: Sera were collected from normal or CKD rats at various times and MMP-2 and MMP-9 levels determined by ELISA or zymography. Aorta tissue was harvested at sacrifice for RT-PCR and immunostaining. Calcification of aorta rings was assessed with MMP inhibitors. Results: There was an increase in MMP-2, MMP-9, TIMP-1, and RUNX-2 expression in the aorta with progressive CKD, and increased MMP-2 activity in the serum. Immunostaining revealed increased expression of MMP-2 and MMP-9 in areas of aorta calcification. There was also an upregulation of MMP-2 and MMP-9 in vascular smooth muscle cells (VSMC) from CKD rats. MMP inhibitors decreased calcification of aorta rings from normal and CKD rats. High phosphorus increased MMP-2 and MMP-9 expressions in VSMC from normal rats but not from CKD rats. Conclusion: MMP-2 and MMP-9 expression and activity are increased with progressive CKD, and blockade of MMP activity can inhibit arterial calcification. These data suggest degradation of the extracellular matrix is a critical step in the pathogenesis of arterial calcification in CKD.

Keywords:
Matrix metalloproteinase, Gelatinase, Vascular calcification, Chronic kidney disease
1.
Moe SM, Chen NX: Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol 2008;19:213–216.
2.
Ortega N, Behonick DJ, Werb Z: Matrix remodeling during endochondral ossification. Trends Cell Biol 2004;14:86–93.
3.
Lijnen HR: Metalloproteinases in development and progression of vascular disease. Pathophysiol Haemost Thromb 2003;33:275–281.
4.
Back M, Ketelhuth DF, Agewall S: Matrix metalloproteinases in atherothrombosis. Prog Cardiovasc Dis 2010;52:410–428.
5.
Beaudeux JL, Giral P, Bruckert E, Foglietti MJ, Chapman MJ: Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives. Clin Chem Lab Med 2004;42:121–131.
6.
Pawlak K, Pawlak D, Mysliwiec M: Serum matrix metalloproteinase-2 and increased oxidative stress are associated with carotid atherosclerosis in hemodialyzed patients. Atherosclerosis 2007;190:199–204.
7.
Fondard O, Detaint D, Iung B, et al: Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors. Eur Heart J 2005;26:1333–1341.
8.
Liu PY, Tsai WC, Lin CC, Hsu CH, Haung YY, Chen JH: Invasive measurements of pulse wave velocity correlate with the degree of aortic valve calcification and severity associated with matrix metalloproteinases in elderly patients with aortic valve stenosis. Clin Sci (Lond) 2004;107:415–422.
9.
Qin X, Corriere MA, Matrisian LM, Guzman RJ: Matrix metalloproteinase inhibition attenuates aortic calcification. Arterioscler Thromb Vasc Biol 2006;26:1510–1516.
10.
Moe SM, Seifert MF, Chen NX, et al: R-568 reduces ectopic calcification in a rat model of chronic kidney disease-mineral bone disorder (CKD-MBD). Nephrol Dial Transplant 2009;24:2371–2377.
11.
Moe SM, Chen NX, Seifert MF, et al: A rat model of chronic kidney disease-mineral bone disorder. Kidney Int 2009;75:176–184.
12.
El Bedoui J, Oak MH, Anglard P, Schini-Kerth VB: Catechins prevent vascular smooth muscle cell invasion by inhibiting MT1-MMP activity and MMP-2 expression. Cardiovasc Res 2005;67:317–325.
13.
Moe SM, Duan D, Doehle BP, O’Neill KD, Chen NX: Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int 2003;63:1003–1011.
14.
Lomashvili KA, Cobbs S, Hennigar RA, Hardcastle KI, O’Neill WC: Phosphate-induced vascular calcification: role of pyrophosphate and osteopontin. J Am Soc Nephrol 2004;15:1392–1401.
15.
Chen NX, Chen X, O’Neill KD, Atkinson SJ, Moe SM: RhoA/Rho kinase (ROCK) alters fetuin-A uptake and regulates the calcification in bovine vascular smooth muscle cells (BVSMC). Am J Physiol Renal Physiol 2010;299:F674–F680.
16.
Kieffer P, Giummelly P, Schjoth B, et al: Activation of metalloproteinase-2, loss of matrix scleroprotein content and coronary artery calcification. Atherosclerosis 2001;157:251–254.
17.
Basalyga DM, Simionescu DT, Xiong W, Baxter BT, Starcher BC, Vyavahare NR: Elastin degradation and calcification in an abdominal aorta injury model: role of matrix metalloproteinases. Circulation 2004;110:3480–3487.
18.
Chung AW, Yang HH, Kim JM, et al: Upregulation of matrix metalloproteinase-2 in the arterial vasculature contributes to stiffening and vasomotor dysfunction in patients with chronic kidney disease. Circulation 2009;120:792–801.
19.
Chung AW, Yang HH, Sigrist MK, et al: Matrix metalloproteinase-2 and -9 exacerbate arterial stiffening and angiogenesis in diabetes and chronic kidney disease. Cardiovasc Res 2009;84:494–504.
20.
Peiskerova M, Kalousova M, Kratochvilova M, et al: Fibroblast growth factor 23 and matrix metalloproteinases in patients with chronic kidney disease: are they associated with cardiovascular disease? Kidney Blood Press Res 2009;32:276–283.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.